Vaxcyte (NASDAQ:PCVX) Announces Quarterly Earnings Results

Vaxcyte (NASDAQ:PCVX) posted its quarterly earnings results on Tuesday. The company reported ($1.02) EPS for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.14, Zacks reports.

Vaxcyte Stock Performance

Vaxcyte stock opened at $79.35 on Wednesday. Vaxcyte has a one year low of $58.10 and a one year high of $121.06. The stock has a fifty day moving average of $85.25 and a 200 day moving average of $95.00. The stock has a market cap of $9.89 billion, a PE ratio of -17.25 and a beta of 0.98.

Insiders Place Their Bets

In other news, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $83.66, for a total transaction of $669,280.00. Following the transaction, the chief operating officer now owns 205,695 shares in the company, valued at $17,208,443.70. This trade represents a 3.74 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Grant Pickering sold 15,000 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $92.45, for a total transaction of $1,386,750.00. Following the sale, the chief executive officer now directly owns 450,301 shares of the company’s stock, valued at approximately $41,630,327.45. The trade was a 3.22 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 76,616 shares of company stock valued at $6,766,481. Insiders own 3.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on PCVX shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research report on Wednesday, November 6th. The Goldman Sachs Group assumed coverage on Vaxcyte in a report on Friday, December 20th. They set a “buy” rating and a $135.00 price target on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $140.00 price objective on shares of Vaxcyte in a research report on Wednesday. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $145.71.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.